RxDoctor Payments Data

John Kersteff, MD

Internal Medicine · Plainfield, INNPI 1942295936

Payments from drug & device makers

$618in general payments, 2019–2025

Across 35 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$480
  • Abbott$33
  • Novo Nordisk$31
  • Supernus Pharmaceuticals, Inc.$22
  • Sanofi Pasteur Inc.$17
  • GSK$12
  • plus $23 from 2 others

What the payments were for

  • Food & beverage$59897%
  • Education$203%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$618 in reported general payments places this provider in the 70th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$136,695
Medicare patients
349
Services billed
1,484

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide76$103,334
EliquisApixaban100$92,834
OzempicSemaglutide80$88,034
JardianceEmpagliflozin53$67,543
TrulicityDulaglutide57$67,135
JanuviaSitagliptin Phosphate38$44,291
Breo ElliptaFluticasone/Vilanterol50$28,098
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog23$24,006
TradjentaLinagliptin23$20,241
Tresiba Flextouch U-100Insulin Degludec12$11,873
Lantus SolostarInsulin Glargine,hum.Rec.Anlog69$9,438
DuleraMometasone/Formoterol13$8,986
JanumetSitagliptin Phos/Metformin Hcl13$8,258
Incruse ElliptaUmeclidinium Bromide11$7,212
Fluticasone-SalmeterolFluticasone Propion/Salmeterol35$7,116

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$480$170,469133 claims
Novo NordiskOzempic$31$88,03480 claims
GSKBreo Ellipta, Incruse Ellipta$12$35,31061 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Plainfield

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →